Brief: Allovir Announces Positive Final Results From Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Of Posoleucel In Kidney Transplant Recipients With Bk Viremia

Kalaris Therapeutics

15/02/2023 13:12

Feb 15 (Reuters) - Allovir Inc  ALVR.O :
    * ALLOVIR ANNOUNCES POSITIVE FINAL RESULTS FROM RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF POSOLEUCEL IN
KIDNEY TRANSPLANT RECIPIENTS WITH BK VIREMIA
    * ALLOVIR INC - REPEAT ADMINISTRATION OF POSOLEUCEL WAS
GENERALLY
WELL TOLERATED, WITH BALANCED SAFETY ACROSS POSOLEUCEL DOSING
GROUPS AND PLACEBO

Source text for Eikon:  ID:nBw1bYXqHa 
Further company coverage:  ALVR.O 
 ((Reuters.Briefs@thomsonreuters.com;;))